<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548033" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548033/" /><meta name="ncbi_pagename" content="Penicillins (2nd Generation) - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Penicillins (2nd Generation) - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Penicillins (2nd Generation)" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/10/20" /><meta name="citation_pmid" content="31643364" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548033/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Penicillins (2nd Generation)" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/10/20" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548033/" /><meta name="description" content="Three major penicillinase-resistant penicillins are available in the United States: dicloxacillin (dye klox&quot; a sil' in), oxacillin (ox&quot; a sil' in) and nafcillin (naf sil' in). Dicloxacillin is orally available; oxacillin and nafcillin have both oral and parenteral formulations, the latter being given by the intramuscular or intravenous route. Other formulations available abroad or in the past include methicillin, cloxacillin and flucloxacillin, which have been associated with a higher frequency of side effects including hepatic injury. The major indications for dicloxacillin, oxacillin and nafcillin are moderate-to-serious infections with susceptible penicillinase-producing staphylococci; these agents are also active against organisms susceptible to natural penicillins, but are less active than the natural penicillins." /><meta name="og:title" content="Penicillins (2nd Generation)" /><meta name="og:type" content="book" /><meta name="og:description" content="Three major penicillinase-resistant penicillins are available in the United States: dicloxacillin (dye klox&quot; a sil' in), oxacillin (ox&quot; a sil' in) and nafcillin (naf sil' in). Dicloxacillin is orally available; oxacillin and nafcillin have both oral and parenteral formulations, the latter being given by the intramuscular or intravenous route. Other formulations available abroad or in the past include methicillin, cloxacillin and flucloxacillin, which have been associated with a higher frequency of side effects including hepatic injury. The major indications for dicloxacillin, oxacillin and nafcillin are moderate-to-serious infections with susceptible penicillinase-producing staphylococci; these agents are also active against organisms susceptible to natural penicillins, but are less active than the natural penicillins." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548033/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/PenicillinSecondGen/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548033/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8DDE0504671B2100000000065F01D8.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548033_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548033_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/PenicillinFirstGen/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/PenicillinThirdGen/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548033_"><span class="title" itemprop="name">Penicillins (2nd Generation)</span></h1><p class="small">Last Update: <span itemprop="dateModified">October 20, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="PenicillinSecondGen.OVERVIEW"><h2 id="_PenicillinSecondGen_OVERVIEW_">OVERVIEW</h2><p>The penicillinase-resistant [also referred to as second generation penicillins] are semisynthetic modifications of natural penicillins that are resistant to bacterial enzyme beta-lactamase, which accounts for typical penicillin resistance. The natural penicillins from which the second generation penicillins are made are bactericidal antibiotics naturally derived from the mold, Penicillium chrysogenum. Their basic structure includes a thiazolidine ring connected to a beta-lactam ring with a variable side chain. As a class, the penicillins bind to bacterial proteins and inhibit synthesis of the bacterial cell wall, causing cell lysis particularly in rapidly growing organisms. Bacterial resistance to penicillin is usually mediated by beta-lactamase, an enzyme which destroys the beta-lactam ring of penicillin, rendering it inactive. The penicillinase-resistant penicillins resist the hydrolysis of the beta-lactam ring by the bacterial enzymes. They are active against most organisms that are susceptible to the natural penicillins (although less active than penicillin G) and have extended coverage against resistant forms.</p><div id="PenicillinSecondGen.Background"><h3>Background</h3><p>Three major penicillinase-resistant penicillins are available in the United States: dicloxacillin (dye klox" a sil' in), oxacillin (ox" a sil' in) and nafcillin (naf sil' in). Dicloxacillin is orally available; oxacillin and nafcillin have both oral and parenteral formulations, the latter being given by the intramuscular or intravenous route. Other formulations available abroad or in the past include methicillin, cloxacillin and flucloxacillin, which have been associated with a higher frequency of side effects including hepatic injury. The major indications for dicloxacillin, oxacillin and nafcillin are moderate-to-serious infections with susceptible penicillinase-producing staphylococci; these agents are also active against organisms susceptible to natural penicillins, but are less active than the natural penicillins.</p></div><div id="PenicillinSecondGen.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Three forms of liver injury have been attributed to the penicillinase-resistant and other penicillins. The first is a transient and usually asymptomatic elevation in serum aminotransferase levels that occurs with high dose intravenous therapy with oxacillin (Case 1, Oxacillin) and rarely with standard penicillins (Case 1, Penicillin G). This reaction has not been described with nafcillin or dicloxacillin and patients can be safety switched to these or other forms of penicillin in the face of oxacillin injury. This form of penicillin-induced liver injury occurs only with high dose therapy that is likely due to direct hepatotoxicity.</p><p>The second form of hepatotoxicity occurs in patients with hypersensitivity reactions to the penicillin (Case 2, Penicillin G). Generally, the liver injury is mild and is overshadowed by the allergic phenomena (rash, fever, facial edema, anaphylaxis). Mild elevations of serum aminotransferase or alkaline phosphatase without jaundice are not uncommon in patients with severe penicillin reactions, and the abnormalities generally resolve rapidly with improvement in the allergic features.</p><p>The third form of hepatotoxicity is an idiosyncratic, usually self-limited cholestatic hepatitis that occurs within 1 to 6 weeks of initiation of therapy and is quite rare, described only in single case reports with oxacillin, nafcillin and dicloxacillin (Case 1, nafcillin and Case 1, dicloxacillin). This injury probably represents a class effect and patients who develop idiosyncratic liver injury due to one of the penicillinase-resistant penicillins should avoid other agents in this class. This type of reaction is much more common with flucloxacillin, an agent that is available in Australia and some countries in Europe, but not in the United States. In addition, rare cases of flucloxacillin associated liver injury have resulted in vanishing bile duct syndrome has well as instances of acute liver failure leading to liver transplantation or death. These more serious complications of drug induced liver injury have been less frequent with use of the other penicillinase-resistant penicillins.</p><p>The idiosyncratic hepatic injury caused by the second generation penicillins is probably due to hypersensitivity. The role of immunologic pathways in liver injury has been best shown with flucloxacillin, which is strongly associated with the presence of the HLA-B*57:01 allele (which also predicts abacavir hypersensitivity). Immunologic studies have begun to elucidate the reasons for the HLA association and hypersensitivity to abacavir and flucloxacillin, and a similar mechanism possibly underlies the idiosyncratic, typically cholestatic jaundice caused by dicloxacillin and other second generation penicillins. However, the incidence of liver injury due to flucloxacillin and dicloxacillin is rare and is uncommon even among persons with HLA-B*57:01, so that screening for this allele is unlikely to be practicable in preparation of using these antibiotics.</p><p>Drug Class: <a href="/books/n/livertox/Antiinfective/">Antiinfective Agents</a></p><p>Dicloxacillin, nafcillin, and oxacillin are discussed separately with individual clinical cases, histology and specific references. General references to the hepatotoxicity of the 2<sup>nd</sup> generation penicillins and to cloxacillin, methicillin, and flucloxacillin are given below.</p><p>The following are links to each drug record:</p><ul><li class="half_rhythm"><div><a href="/books/n/livertox/Dicloxacillin/">Dicloxacillin</a></div></li><li class="half_rhythm"><div><a href="/books/n/livertox/Nafcillin/">Nafcillin</a></div></li><li class="half_rhythm"><div><a href="/books/n/livertox/Oxacillin/">Oxacillin</a></div></li><li class="half_rhythm"><div>Cloxacillin</div></li><li class="half_rhythm"><div>Flucloxacillin</div></li><li class="half_rhythm"><div>Methicillin</div></li></ul></div></div><div id="PenicillinSecondGen.CHEMICAL_FORMULAS_AN"><h2 id="_PenicillinSecondGen_CHEMICAL_FORMULAS_AN_">CHEMICAL FORMULAS AND STRUCTURES</h2><div id="PenicillinSecondGen.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548033/table/PenicillinSecondGen.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__PenicillinSecondGen.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_PenicillinSecondGen.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_PenicillinSecondGen.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO</th><th id="hd_h_PenicillinSecondGen.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_PenicillinSecondGen.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Cloxacillin</td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971202" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">61-72-3</a></td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C19-H18-Cl-N3-O5-S</td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134971202" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134971202" alt="image 134971202 in the ncbi pubchem database" /></a></td></tr><tr><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Dicloxacillin</td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134981835" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">3116-76-5</a></td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C19-H17-Cl2-N3-O5-S</td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134981835" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134981835" alt="image 134981835 in the ncbi pubchem database" /></a></td></tr><tr><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Flucloxacillin Floxacillin [USAN]</td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134984533" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">5250-39-5</a></td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C19-H17-Cl-F-N3-O5-S</td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134984533" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134984533" alt="image 134984533 in the ncbi pubchem database" /></a></td></tr><tr><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Methicillin</td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134970879" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">61-32-5</a></td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C17-H20-N2-O6-S</td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134970879" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134970879" alt="image 134970879 in the ncbi pubchem database" /></a></td></tr><tr><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Nafcillin</td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134975099" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">147-52-4</a></td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C21-H22-N2-O5-S</td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134975099" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134975099" alt="image 134975099 in the ncbi pubchem database" /></a></td></tr><tr><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Oxacillin</td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134972946" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">66-79-5</a></td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C19-H19-N3-O5-S</td><td headers="hd_h_PenicillinSecondGen.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134972946" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134972946" alt="image 134972946 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="PenicillinSecondGen.ANNOTATED_BIBLIOGRAP"><h2 id="_PenicillinSecondGen_ANNOTATED_BIBLIOGRAP_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 20 October 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="PenicillinSecondGen.REF.zimmerman.1999">Zimmerman HJ. Synthetic penicillins. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999. p. 596-8.<div><i>(Expert review of penicillins and liver injury published in 1999).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.moseley.2013">Moseley RH. Hepatotoxicity of antimicrobials and antifungal agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 463-82.<div><i>(Review of hepatotoxicity of antibiotics mentions that liver injury from the penicillins is very rare, and is usually cholestatic for the oxypenicillins such as dicloxacillin and cloxacillin).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.macdougall.2018">MacDougall C. Penicillins, cephalosporins, and other &#x003b2;-lactam antibiotics. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1023-38.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.freedman.1965.34">Freedman MA. Oxacillin&#x02014;apparent hematologic and hepatic toxicity. <span><span class="ref-journal">Rocky Mt Med J. </span>1965;<span class="ref-vol">62</span>:34–6.</span> [<a href="/pubmed/14224480" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14224480</span></a>]<div><i>(33 year old woman developed AST elevations to ~220 U/L, atypical lymphocytosis and eosinophilia after 2.5 months of high dose oral oxacillin, complicated by bone marrow suppression and breakthrough in chronic osteomyelitis).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.pas.1965.674">Pas AT, Quinn EL. Cholestatic hepatitis following the administration of sodium oxacillin. <span><span class="ref-journal">JAMA. </span>1965;<span class="ref-vol">191</span>:674–5.</span> [<a href="/pubmed/14242432" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14242432</span></a>]<div><i>(65 year old woman developed itching and jaundice the week after stopping a 4 week course of oral oxacillin [bilirubin 2.2 mg/dL, Alk P ~twice elevated, AST 76 U/L], resolving within 8 weeks).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.dismukes.1973.861">Dismukes WE. Oxacillin-induced hepatic dysfunction. <span><span class="ref-journal">JAMA. </span>1973;<span class="ref-vol">226</span>:861–3.</span> [<a href="/pubmed/4800332" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4800332</span></a>]<div><i>(3 cases of ALT elevations, fever and nausea arising 11-24 days after starting high dose intravenous oxacillin therapy, with rapid reversal on stopping).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.olans.1976.835">Olans RN, Weiner LB. Reversible oxacillin hepatotoxicity. <span><span class="ref-journal">J Pediatr. </span>1976;<span class="ref-vol">89</span>:835–8.</span> [<a href="/pubmed/978335" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 978335</span></a>]<div><i>(8 instances of ALT elevations [peak values 31-1359 U/L] without jaundice [2 had eosinophilia] after 8-25 days of intravenous oxacillin in children or young adults, with rapid resolution; no recurrence when switched to nafcillin).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.bruckstein.1978.519">Bruckstein AH, Attia AA. Oxacillin hepatitis. Two patients with liver biopsy, and review of the literature. <span><span class="ref-journal">Am J Med. </span>1978;<span class="ref-vol">64</span>:519–22.</span> [<a href="/pubmed/637061" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 637061</span></a>]<div><i>(Two injection drug users treated with high dose oxacillin [12-16 g/day] for endocarditis developed increased AST levels [10-40 times ULN], with mild symptoms but no change in Alk P or bilirubin and nonspecific biopsy findings, arising after 2-3 weeks and resolving rapidly with stopping).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.goldstein.1978.171">Goldstein LI, Granoff M, Waisman J. Hepatic injury due to oxacillin administration. <span><span class="ref-journal">Am J Gastroenterol. </span>1978;<span class="ref-vol">70</span>:171–4.</span> [<a href="/pubmed/717369" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 717369</span></a>]<div><i>(21 year old male injection drug used developed aminotransferase elevations [ALT 806 U/L, AST 388 U/L, 15% eosinophils] 20 days after starting intravenous oxacillin [12 g/day], with biopsy showing hepatitis, rapid recovery).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.onorato.1978.497">Onorato IM, Axelrod JL. Hepatitis from intravenous high-dose oxacillin therapy: findings in an adult inpatient population. <span><span class="ref-journal">Ann Intern Med. </span>1978;<span class="ref-vol">89</span>:497–500.</span> [<a href="/pubmed/697229" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 697229</span></a>]<div><i>(Review of experience with high dose oxacillin revealed 8 cases of liver injury, rising 3-19 days after start of therapy with fever and mild GI symptoms, ALT 2 to 15 times ULN, Alk P minimally increased, and no jaundice; resolving in 1 week; compared to control group, a history of penicillin allergy was given in 3 cases, but not controls).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.dangelo.1979.442">D'Angelo LJ. Oxacillin and hepatotoxicity. <span><span class="ref-journal">Ann Intern Med. </span>1979;<span class="ref-vol">90</span>:442.</span> [<a href="/pubmed/426429" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 426429</span></a>]<div><i>(Letter commenting on article by Onorato &#x00026; Axelrod, without new data).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.taylor.1979.857">Taylor C, Corrigan K, Steen S, Craig C. Oxacillin and hepatitis. <span><span class="ref-journal">Ann Intern Med. </span>1979;<span class="ref-vol">90</span>:857–8.</span> [<a href="/pubmed/434706" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 434706</span></a>]<div><i>(Letter in response to Onorato &#x00026; Axelrod describing 24 year old man who developed ALT elevations [226 U/], with rash and eosinophilia after 27 days of intravenous oxacillin therapy [8 g/day], rapidly resolving upon switching to nafcillin).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.pollock.1978.915">Pollock AA, Berger SA, Simberkoff MS, Rahal JJ Jr. Hepatitis associated with high-dose oxacillin therapy. <span><span class="ref-journal">Arch Intern Med. </span>1978;<span class="ref-vol">138</span>:915–7.</span> [<a href="/pubmed/646563" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 646563</span></a>]<div><i>(Prospective study of liver tests in 41 patients during intravenous oxacillin therapy; 15 had ALT elevations, but only 5 were attributed to oxacillin, 12-23 g/day arising 5-24 days after starting, peak ALT values 5-20 times ULN, mild Alk P elevation in 4, but normal bilirubin in all, and resolution in 4-16 days of stopping; no eosinophilia, fever or symptoms).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.halloran.1979.376">Halloran TJ, Clague MD. Hepatitis associated with high-dose oxacillin therapy. <span><span class="ref-journal">Arch Intern Med. </span>1979;<span class="ref-vol">139</span>:376–7.</span> [<a href="/pubmed/426588" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 426588</span></a>]<div><i>(Letter in response to Pollock [1978] describing 16 year old girl with no history of injection drug use who developed AST elevations [peak 140 U/L], starting after 9 days of intravenous oxacillin, rapid resolution upon stopping).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.enat.1980.982">Enat R, Pollack S, Ben-Arieh Y, Livni E, Barzilai D. Cholestatic jaundice caused by cloxacillin: macrophage inhibition factor test in preventing rechallenge with hepatotoxic drugs. <span><span class="ref-journal">Br Med J. </span>1980;<span class="ref-vol">280</span>:982–3.</span> [<a href="/pmc/articles/PMC1601139/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1601139</span></a>] [<a href="/pubmed/7417768" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7417768</span></a>]<div><i>(69 year old woman developed jaundice 2 weeks after a course of ampicillin and cloxacillin [bilirubin 14.9 mg/dL, AST normal, Alk P ~5 times ULN], with recurrence within 4 days of rechallenge [bilirubin 9.3 mg/dL, ALT normal, Alk P twice ULN], positive macrophage inhibition factor test).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.williams.1981.470">Williams CN, Malatjalian DA. Severe penicillin-induced cholestasis in a 91-year-old woman. <span><span class="ref-journal">Dig Dis Sci. </span>1981;<span class="ref-vol">26</span>:470–3.</span> [<a href="/pubmed/7249889" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7249889</span></a>]<div><i>(91 year old woman was given both penicillin G and cloxacillin for 11 days when cholestatic hepatitis arose, bilirubin rising to 24 mg/dL, but recovery in 2 months, most likely due to cloxacillin).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.lobatto.1982.47">Lobatto S, Dijkmans BA, Mattie H, Van Hooff JP. Flucloxacillin-associated liver damage. <span><span class="ref-journal">Neth J Med. </span>1982;<span class="ref-vol">25</span>:47–8.</span> [<a href="/pubmed/7070561" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7070561</span></a>]<div><i>(63 year old woman on renal dialysis had mild ALT elevation [twice ULN] after a few days of intravenous floxacillin and cloxacillin, with positive rechallenge to oral flucloxacillin [ALT rose from 14 to 74 U/L within 1 day]).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.nahata.1982.117">Nahata MC, DeBolt SL, Powell DA. Adverse effects of methicillin, nafcillin and oxacillin in pediatric patients. <span><span class="ref-journal">Dev Pharmacol Ther. </span>1982;<span class="ref-vol">4</span>:117–23.</span> [<a href="/pubmed/7172968" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7172968</span></a>]<div><i>(Prospective study of children treated with intravenous methicillin [28], nafcillin [32] or oxacillin [8]; minimal ALT elevations occurred in 1 on nafcillin and 1 on oxacillin; no jaundice).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.miller.1983.465">Miller WI, Souney PF, Chang JT. Hepatic dysfunction following nafcillin and cephalothin therapy in a patient with a history of oxacillin hepatitis. <span><span class="ref-journal">Clin Pharm. </span>1983;<span class="ref-vol">2</span>:465–8.</span> [<a href="/pubmed/6627877" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6627877</span></a>]<div><i>(Mild ALT elevations after 13 days of high dose oxacillin [18 g/day], similar increase after nafcillin and again with cephalosporin in a male injection drug user with probable chronic hepatitis C, which might have accounted for ALT fluctuations).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.bengtsson.1985.125">Bengtsson F, Flor&#x000e9;n CH, H&#x000e4;gerstrand I, S&#x000f6;derstr&#x000f6;m C, Aberg T. Flucloxacillin-induced cholestatic liver damage. <span><span class="ref-journal">Scand J Infect Dis. </span>1985;<span class="ref-vol">17</span>:125–8.</span> [<a href="/pubmed/3992199" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3992199</span></a>]<div><i>(2 cases of cholestatic hepatitis of moderate severity arising 4-5 weeks after starting oral cloxacillin, resolution in 6-8 weeks).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.tauris.1985.567">Tauris P, J&#x000f8;rgensen NF, Petersen CM, Albertsen K. Prolonged severe cholestasis induced by oxacillin derivatives. A report on two cases. <span><span class="ref-journal">Acta Med Scand. </span>1985;<span class="ref-vol">217</span>:567–9.</span> [<a href="/pubmed/4025011" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4025011</span></a>]<div><i>(2 case reports: 65 year old man with osteomyelitis developed jaundice and pruritus 6 weeks after starting flucloxacillin [bilirubin ~10 mg/dL, AST 1.5 times ULN, Alk P 3 times ULN], biopsy showing cholestasis, resolving within 8 weeks of stopping; 21 year old man with osteomyelitis developed jaundice 9 weeks after starting dicloxacillin [bilirubin ~4 mg/dL, AST 119 U/L, Alk P 814 U/L], resolving within 6 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.aderka.1986.1084">Aderka D, Livni E, Salamon F, Weinberger A, Pinkhas J. Use of macrophage inhibition factor and mast-cell degranulation tests for diagnosis of cloxacillin-induced cholestasis. <span><span class="ref-journal">Am J Gastroenterol. </span>1986;<span class="ref-vol">81</span>:1084–6.</span> [<a href="/pubmed/3776960" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3776960</span></a>]<div><i>(58 year old man took 10 days of cloxacillin and developed jaundice 3 days later [peak bilirubin 18.7 mg/dL, ALT 450 U/L, Alk P 436 IU, no eosinophilia]; had positive macrophage inhibition factor and mast cell degranulation tests in response to cloxacillin).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.kleinman.1986.77">Kleinman MS, Presberg JE. Cholestatic hepatitis after dicloxacillin-sodium therapy. <span><span class="ref-journal">J Clin Gastroenterol. </span>1986;<span class="ref-vol">8</span>:77–8.</span> [<a href="/pubmed/3701014" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3701014</span></a>]<div><i>(56 year old man developed jaundice and pruritus 2-3 weeks after a 5 day course of dicloxacillin [bilirubin rising to 13 mg/dL, AST 225 U/L, Alk P 318 U/L], without rash, eosinophilia or fever, requiring 10 weeks to resolve).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.konikoff.1986.1082">Konikoff F, Alcalay J, Halevy J. Cloxacillin-induced cholestatic jaundice. <span><span class="ref-journal">Am J Gastroenterol. </span>1986;<span class="ref-vol">81</span>:1082–3.</span> [<a href="/pubmed/3776959" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3776959</span></a>]<div><i>(77 year old woman developed fever and pruritus 5 days after starting oral cloxacillin [bilirubin 3.6 mg/dL, AST 97 U/L, Alk P 497 U/L], resolving within 5 weeks; history revealed a similar response to a previous course of oral cloxacillin, thus explaining the short latency period).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.deboever.1987.483">Deboever G. Cholestatic jaundice due to derivatives of oxacillin. <span><span class="ref-journal">Am J Gastroenterol. </span>1987;<span class="ref-vol">82</span>:483.</span> [<a href="/pubmed/3578231" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3578231</span></a>]<div><i>(Letter in response to Konikoff [1986] describing 75 year old woman with cholestatic hepatitis [bilirubin 12.8 mg/dL, ALT 57 U/L, Alk P 868 U/L] arising 3 days after starting flucloxacillin, resolving in 2 months).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.victorino.1987.987">Victorino RM, Maria VA, Correia AP, de Moura C. Floxacillin-induced cholestatic hepatitis with evidence of lymphocyte sensitization. <span><span class="ref-journal">Arch Intern Med. </span>1987;<span class="ref-vol">147</span>:987–9.</span> [<a href="/pubmed/3579450" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3579450</span></a>]<div><i>(45 year old man developed prolonged cholestatic hepatitis arising 15 days after starting oral floxacillin [bilirubin rising from 11 to 40.6 mg/dL, ALT 490 U/L, Alk P 171 U/L], ultimately responding to prednisone therapy).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF27">[Risk of liver reactions after treatment with flucloxacillin] Lakartidningen 1989; 86: 977-8. Swedish. [<a href="/pubmed/2927200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2927200</span></a>]</div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.turner.1989.701">Turner IB, Eckstein RP, Riley JW, Lunzer MR. Prolonged hepatic cholestasis after flucloxacillin therapy. <span><span class="ref-journal">Med J Aust. </span>1989;<span class="ref-vol">151</span>:701–5.</span> [<a href="/pubmed/2593915" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2593915</span></a>]<div><i>(5 cases of cholestatic hepatitis arising after stopping flucloxacillin, latency 13-35 days [bilirubin 13.3-38.2 mg/dL, ALT 85-525 U/L, Alk P 263-1580 U/L], with prolonged jaundice and abnormal liver tests still present 4-9 months later).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.miros.1990.251">Miros M, Kerlin P, Walker N, Harris O. Flucloxacillin induced delayed cholestatic hepatitis. <span><span class="ref-journal">Aust N Z J Med. </span>1990;<span class="ref-vol">20</span>:251–3.</span> [<a href="/pubmed/2372276" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2372276</span></a>]<div><i>(6 cases of cholestatic hepatitis 17-28 days after starting flucloxacillin, with prolonged course and 3 who still had marked Alk P elevations 6 months later).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.pascual.1990.335">Pascual J, Orofino L, Marc&#x000e9;n R, Quereda C, Ortu&#x000f1;o J. Cloxacillin-induced cholestasis in a renal allograft patient with chronic hepatitis. <span><span class="ref-journal">Am J Gastroenterol. </span>1990;<span class="ref-vol">85</span>:335–6.</span> [<a href="/pubmed/2106780" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2106780</span></a>]<div><i>(Man with renal transplant and advanced chronic hepatitis C developed sudden onset of itching and worsening of jaundice [bilirubin rising from 4.1 to 22 mg/dL] 3 days after starting intravenous cloxacillin [8 grams/day], with rapid reversal on stopping).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.fairley.1992.679">Fairley CK, Boyd I, Purcell P, McNeil J. Flucloxacillin jaundice. <span><span class="ref-journal">Lancet. </span>1992;<span class="ref-vol">339</span>:679.</span> [<a href="/pubmed/1347364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1347364</span></a>]<div><i>(Letter describing increase use of flucloxacillin in Australia [from 12,136 in 1986 to 1,000,000 prescriptions yearly in 1990] and increasing adverse events reported [from 4 in 1987 to 64 in 1990]; worldwide, 255 hepatic adverse events reported).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.lestico.1992.985">Lestico MR, Vick KE, Hetsko CM. Hepatic and renal dysfunction following nafcillin administration. <span><span class="ref-journal">Ann Pharmacother. </span>1992;<span class="ref-vol">26</span>:985–90.</span> [<a href="/pubmed/1504413" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1504413</span></a>]<div><i>(Four cases of elevations in creatinine, BUN and bilirubin within 4 days of starting iv nafcillin, but most patients had abnormal liver tests before therapy; minimal change in AST and Alk P and all patients were septic and also received rifampin and/or gentamicin).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.olsson.1992.154">Olsson R, Wiholm BE, Sand C, Zettergren L, Hultcrantz R, Myrhed M. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. <span><span class="ref-journal">J Hepatol. </span>1992;<span class="ref-vol">15</span>:154–61.</span> [<a href="/pubmed/1506634" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1506634</span></a>]<div><i>(54 year old woman developed prolonged cholestasis [peak bilirubin 24 mg/dL] after an 18 day course of flucloxacillin leading to cirrhosis and liver transplantation 7 years later; possibly vanishing bile duct syndrome. In a review of Swedish adverse drug reaction reports, 77 flucloxacillin cases were found between 1981-90 compared to only 16 for dicloxacillin and 9 for cloxacillin, fever and eosinophilia in half, mostly cholestatic and mixed enzymes, occasional hepatocellular, older age was a risk factor).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.derby.1993.596">Derby LE, Jick H, Henry DA, Dean AD. Cholestatic hepatitis associated with flucloxacillin. <span><span class="ref-journal">Med J Aust. </span>1993;<span class="ref-vol">158</span>:596–600.</span> [<a href="/pubmed/8479374" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8479374</span></a>]<div><i>(Survey of 600 general practices in the UK with 132,087 patients who received flucloxacillin, 10 cases of unexplained cholestatic liver injury &#x0003c;45 days [mean~4 weeks] afterwards compared to 3 cases after tetracycline; estimated risk was 7.6 per 100,000 users).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.jick.1994.525">Jick H, Derby LE, Dean AD, Henry DA. Flucloxacillin and cholestatic hepatitis. <span><span class="ref-journal">Med J Aust. </span>1994;<span class="ref-vol">160</span>:525.</span> [<a href="/pubmed/8170433" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8170433</span></a>]<div><i>(Follow up of study by Derby et al.; risk of flucloxacillin cholestatic hepatitis in a new cohort was 6.5 per 100,000 users, with a rate similar to their previous estimate).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.eckstein.1993.223">Eckstein RP, Dowsett JF, Lunzer MR. Flucloxacillin induced liver disease: histopathological findings at biopsy and autopsy. <span><span class="ref-journal">Pathology. </span>1993;<span class="ref-vol">25</span>:223–8.</span> [<a href="/pubmed/8265236" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8265236</span></a>]<div><i>(Liver histology from 13 cases of flucloxacillin induced liver injury from Australia; ages 37-83 years given flucloxacillin for 5-23 days, onset 7-21 after stopping, mostly cholestatic; histology showed intrahepatic cholestasis, no granulomas, bile ductular injury, 3 of 4 with prolonged course had ductopenia).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.fairley.1993.233">Fairley CK, McNeil JJ, Desmond P, Smallwood R, Young H, Forbes A, Purcell P, et al.  Risk factors for development of flucloxacillin associated jaundice. <span><span class="ref-journal">BMJ. </span>1993;<span class="ref-vol">306</span>:233–5.</span> [<a href="/pmc/articles/PMC1676728/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1676728</span></a>] [<a href="/pubmed/8443520" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8443520</span></a>]<div><i>(Review of cases from the Australia adverse drug reaction system tracing 51 cases and 199 controls; injury was associated with older age, longer therapy, concomitant drugs, but not alcohol, smoking, gender or other drug allergies).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.mazuryk.1993.1960">Mazuryk H, Kastenberg D, Rubin R, Mu&#x000f1;oz SJ. Cholestatic hepatitis associated with the use of nafcillin. <span><span class="ref-journal">Am J Gastroenterol. </span>1993;<span class="ref-vol">88</span>:1960–2.</span> [<a href="/pubmed/8237951" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8237951</span></a>]<div><i>(80 year old developed pruritus and rash after 2 weeks of intravenous nafcillin [8 g/day], with subsequent jaundice [bilirubin rising from 5.7 to 15 mg/dL, ALT 117 U/L, Alk P 1,102 U/L; after month of jaundice, prednisone was started with prompt improvement).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.siegmund.1993.1299">Siegmund JB, Tarshis AM. Prolonged jaundice after dicloxacillin therapy. <span><span class="ref-journal">Am J Gastroenterol. </span>1993;<span class="ref-vol">88</span>:1299–300.</span> [<a href="/pubmed/8338117" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8338117</span></a>]<div><i>(36 year old woman developed fatigue and jaundice 3 weeks after starting dicloxacillin [bilirubin 18.2 mg/dL, ALT 100 U/L, Alk P 312 U/L], with slow recovery even with prednisone; 3 years later, enzymes were still mildly elevated [ALT 44 U/L, Alk P 188 U/L]).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.koek.1994.225">Koek GH, Stricker BH, Blok AP, Schalm SW, Desmet VJ. Flucloxacillin-associated hepatic injury. <span><span class="ref-journal">Liver. </span>1994;<span class="ref-vol">14</span>:225–9.</span> [<a href="/pubmed/7997079" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7997079</span></a>]<div><i>(Description of 11 cases of flucloxacillin hepatotoxicity reported to Dutch Adverse Events Center over 10 years, onset in 10-30 days, cholestatic in 7, mixed in 3; 2 patients died; the rest resolved in an average of 10 weeks).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.saliba.1994.1048">Saliba B, Herbert PN. Oxacillin hepatotoxicity in HIV-infected patients. <span><span class="ref-journal">Ann Intern Med. </span>1994;<span class="ref-vol">120</span>:1048.</span> [<a href="/pubmed/8185140" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8185140</span></a>]<div><i>(Retrospective review found that 81% [9/11] of HIV-positive, but only 4.5% [3/66] of HIV-negative patients receiving iv oxacillin for more than 10 days developed ALT or AST &#x0003e;3 fold elevated).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.desmond.1995.195">Desmond PV. Flucloxacillin hepatitis--an Australian epidemic. <span><span class="ref-journal">Aust N Z J Med. </span>1995;<span class="ref-vol">25</span>:195–6.</span> [<a href="/pubmed/7487684" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7487684</span></a>]<div><i>(Review of Australian experience with flucloxacillin, their most common cause of drug induced liver disease; average age 58 years, onset 16 days after stopping, chronic cholestasis frequent; fatality rate 5%).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.devereaux.1995.81">Devereaux BM, Crawford DH, Purcell P, Powell LW, Roeser HP. Flucloxacillin associated cholestatic hepatitis. An Australian and Swedish epidemic? <span><span class="ref-journal">Eur J Clin Pharmacol. </span>1995;<span class="ref-vol">49</span>:81–5.</span> [<a href="/pubmed/8751026" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8751026</span></a>]<div><i>(Review of literature and history of use and pattern and frequency of hepatic injury from flucloxacillin in Australia, Sweden and UK).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.pillans.1996.315">Pillans PI. Drug associated hepatic reactions in New Zealand: 21 years experience. <span><span class="ref-journal">N Z Med J. </span>1996;<span class="ref-vol">109</span>:315–9.</span> [<a href="/pubmed/8816722" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8816722</span></a>]<div><i>(Flucloxacillin ranked 6th as a cause of liver adverse drug reaction in New Zealand in 1990s).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.presti.1996.180">Presti ME, Janney CG, Neuschwander-Tetri BA. Nafcillin-associated hepatotoxicity. Report of a case and review of the literature. <span><span class="ref-journal">Dig Dis Sci. </span>1996;<span class="ref-vol">41</span>:180–4.</span> [<a href="/pubmed/8565754" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8565754</span></a>]<div><i>(63 year old developed jaundice after 5 days of intravenous nafcillin [bilirubin rising to 40 mg/dL, ALT ~210 U/L, Alk P ~375 U/L], lasting 2 months, previous history of dicloxacillin allergy-rash).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.saab.1996.163">Saab S, Venkataramani A, Yao F. Possible granulomatous hepatitis after dicloxacillin therapy. <span><span class="ref-journal">J Clin Gastroenterol. </span>1996;<span class="ref-vol">22</span>:163–4.</span> [<a href="/pubmed/8742666" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8742666</span></a>]<div><i>(74 year old developed rash 5 days after starting oral dicloxacillin [bilirubin 0.5 mg/dL, ALT 172 U/L, Alk P 183 U/L], biopsy showing a single granuloma and mild nonspecific changes, ultimately resolving within 4 months of stopping).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.goland.1998.59">Goland S, Malnick SD, Gratz R, Feldberg E, Geltner D, Sthoeger ZM. Severe cholestatic hepatitis following cloxacillin treatment. <span><span class="ref-journal">Postgrad Med J. </span>1998;<span class="ref-vol">74</span>:59–60.</span> [<a href="/pmc/articles/PMC2360792/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2360792</span></a>] [<a href="/pubmed/9538497" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9538497</span></a>]<div><i>(77 year old woman developed fever, rash and jaundice 2 weeks after stopping a 2 week course of cloxacillin and ofloxacin with bilirubin 12.9 mg/dL, ALT 144 U/L, Alk P 394 U/L; after a month of jaundice, prednisone introduced with prompt improvement).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.alhomaidhi.2002.650">Al-Homaidhi H, Abdel-Haq NM, El-Baba M, Asmar BI. Severe hepatitis associated with oxacillin therapy. <span><span class="ref-journal">South Med J. </span>2002;<span class="ref-vol">95</span>:650–2.</span> [<a href="/pubmed/12081223" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12081223</span></a>]<div><i>(6 year old girl developed fever, abdominal pain and marked ALT elevation [peak 2,257 U/L] with normal Alk P and bilirubin [0.3 mg/dL] after 14 days of intravenous oxacillin, resolving within 3 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.trevenzoli.2003.324">Trevenzoli M, Cattelan AM, Mencarelli R, Meneghetti F. Severe hepatitis associated with oxacillin therapy. <span><span class="ref-journal">South Med J. </span>2003;<span class="ref-vol">96</span>:324–5.</span> [<a href="/pubmed/12659378" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12659378</span></a>]<div><i>(Letter in response to Al-Homaidhi [2002] describing 33 year old who developed liver injury [bilirubin 1.8 mg/dL, ALT 2440 U/L, Alk P 103 U/L] weeks after receiving a 4 day course of amoxicillin/clavulanate [not oxacillin as suggested by the title]).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.ib__ez.2002.592">Ib&#x000e1;&#x000f1;ez L, P&#x000e9;rez E, Vidal X, Laporte JR. Grup d'Estudi Multic&#x000e8;nteric d'Hepatotoxicitat Aguda de Barcelona (GEMHAB). Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. <span><span class="ref-journal">J Hepatol. </span>2002;<span class="ref-vol">37</span>:592–600.</span> [<a href="/pubmed/12399224" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12399224</span></a>]<div><i>(Survey of 107 cases of acute serious liver disease, not due to viruses, found no instances of drug induced liver injury due to penicillinase-resistant penicillins).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.maraqa.2002.50">Maraqa NF, Gomez MM, Rathore MH, Alvarez AM. Higher occurrence of hepatotoxicity and rash in patients treated with oxacillin, compared with those treated with nafcillin and other commonly used antimicrobials. <span><span class="ref-journal">Clin Infect Dis. </span>2002;<span class="ref-vol">34</span>:50–4.</span> [<a href="/pubmed/11731945" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11731945</span></a>]<div><i>(Retrospective analysis of laboratory tests from 222 children receiving outpatient parenteral oxacillin, nafcillin, clindamycin or other antibiotics found 12 cases of anicteric and self-limited hepatotoxicity, 9 [22%] from oxacillin, all hepatocellular with normal bilirubin, onset in 6-43 days, resolution in 1-3 weeks; none to nafcillin; 1 clindamycin, 1 ceftriaxone and 1 ampicillin/sulbactam/gentamicin).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.sgro.2002.451">Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, et al.  Incidence of drug-induced hepatic injuries: a French population-based study. <span><span class="ref-journal">Hepatology. </span>2002;<span class="ref-vol">36</span>:451–5.</span> [<a href="/pubmed/12143055" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12143055</span></a>]<div><i>(A population based study identified 34 cases of acute drug induced liver injury over a 3 year period, including 10 [25%] due to antibiotics; one was due to cloxacillin with a 5 day latency, mixed serum enzyme pattern and recovery within 2 weeks of stopping).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.bj_rnsson.2005.1095">Bj&#x000f6;rnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. <span><span class="ref-journal">Scand J Gastroenterol. </span>2005;<span class="ref-vol">40</span>:1095–101.</span> [<a href="/pubmed/16165719" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16165719</span></a>]<div><i>(Analysis of all fatal adverse drug event reports of liver injury in Sweden between 1966 and 2002, found 103 cases; most common causes were halothane [n=16], acetaminophen [14], flucloxacillin [9], and TMP-SMZ [6]).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.dobson.2005.487">Dobson JL, Angus PW, Jones R, Crowley P, Gow PJ. Flucloxacillin-induced aplastic anaemia and liver failure. <span><span class="ref-journal">Transpl Int. </span>2005;<span class="ref-vol">18</span>:487–9.</span> [<a href="/pubmed/15773973" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15773973</span></a>]<div><i>(40 year old woman developed aplastic anemia and acute liver failure starting 4 weeks after starting 2 week course of flucloxacillin, reversed by liver transplantation).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.hussaini.2007.15">Hussaini SH, O'Brien CS, Despott EJ, Dalton HR. Antibiotic therapy: a major cause of drug-induced jaundice in southwest England. <span><span class="ref-journal">Eur J Gastroenterol Hepatol. </span>2007;<span class="ref-vol">19</span>:15–20.</span> [<a href="/pubmed/17206072" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17206072</span></a>]<div><i>(Review of causes of non-obstructive jaundice in 347 patients presenting between 1998 and 2004 at a single UK center, 28 were thought to be drug induced liver injury [8.1%] and antibiotics were the most common cause, 32% amoxicillin/clavulanate, 25% flucloxacillin, 18% other).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.lee.2008.146">Lee CY, Chen PY, Huang FL, Chi CS. Reversible oxacillin-associated hepatitis in a 9-month old boy. <span><span class="ref-journal">J Paediatr Child Health. </span>2008;<span class="ref-vol">44</span>:146–8.</span> [<a href="/pubmed/18307421" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18307421</span></a>]<div><i>(9 month old boy given intravenous oxacillin for septic arthritis for 8 days when he developed lethargy and marked elevations in ALT [1568 U/L], with normal Alk P and bilirubin and resolving within 10 days of switching to teicoplanin).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network (DILIN).  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, antimicrobials accounted for 45% of cases with 23 single agent cases due to amoxicillin/clavulanate, 13 nitrofurantoin, 10 fluoroquinolones, 9 macrolides, 9 sulfonamides, 5 cephalosporins, 3 oxacillin, 2 doxycycline, 2 amoxicillin, and one each for gentamicin, imipenem, and clindamycin, but none from dicloxacillin or nafcillin).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.devarbhavi.2010.2396">Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. <span><span class="ref-journal">Am J Gastroenterol. </span>2010;<span class="ref-vol">105</span>:2396–404.</span> [<a href="/pubmed/20648003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20648003</span></a>]<div><i>(313 cases of drug induced liver injury were seen over a 12 year period at a large hospital in Bangalore, India; leading causes were antituberculosis agents [58%], anticonvulsants [11%] and NSAIDs [2%]; specific antibiotic agents included sulfamethoxazole/ trimethoprim [2%] and amoxicillin-clavulanate [1%]).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.ferrajolo.2010.721">Ferrajolo C, Capuano A, Verhamme KMC, Schuemie M, Rossi F, Stricker BH, Sturkenboom CJM. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. <span><span class="ref-journal">Br J Clin Pharmacol. </span>2010;<span class="ref-vol">70</span>:721–8.</span> [<a href="/pmc/articles/PMC2997312/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2997312</span></a>] [<a href="/pubmed/21039766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21039766</span></a>]<div><i>(Among 624,673 adverse drug reports in children in a worldwide pharmacovigilance database, 6595 [1%] were for hepatic injury and antibacterials accounted for 11%, those with the highest adjusted odds ratios being aztreonam, erythromycin, ceftriaxone and minocycline; no mention of penicillins).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.li.2009.269">Li L, Jick H, Jick SS. Updated study on risk of cholestatic liver disease and flucloxacillin. <span><span class="ref-journal">Br J Clin Pharmacol. </span>2009;<span class="ref-vol">68</span>:269–70.</span> [<a href="/pmc/articles/PMC2767292/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2767292</span></a>] [<a href="/pubmed/19694748" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19694748</span></a>]<div><i>(Analysis of UK General Practice Research Database showed risk of cholestatic liver disease within 45 days of first time use of flucloxacillin was stable between 1985-2007 [6.1-8.5/100,000 users compared to 0.3/100,000 users of penicillin V]).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.daly.2009.816">Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, et al.  HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. <span><span class="ref-journal">Nature Genetics. </span>2009;<span class="ref-vol">41</span>:816–9.</span> [<a href="/pubmed/19483685" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19483685</span></a>]<div><i>(Genome-wide association study [GWAS] in 51 cases of flucloxacillin liver injury and 285 controls found an association with a single nucleotide polymorphism linked to HLA-B*5701 [84% in cases vs 5% in controls], the same genotype associated with abacavir hypersensitivity; ~0.2% of persons with this HLA type receiving flucloxacillin develop cholestatic hepatitis, making it likely that other genes or factors are important as well).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group.  Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury including 66 due to antimicrobial agents, but none were attributed to a penicillinase-resistant penicillin).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.leitner.2010.3">Leitner JM, Graninger W, Thalhammer F. Hepatotoxicity of antibacterials: pathomechanisms and clinical data. <span><span class="ref-journal">Infection. </span>2010;<span class="ref-vol">38</span>:3–11.</span> [<a href="/pubmed/20107858" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20107858</span></a>]<div><i>(Review of hepatotoxicity of antibiotics, mentions that cholestatic hepatitis has been reported with many beta-lactams and beta-lactamases inhibitors).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.daly.2010.241">Daly AK. Genome-wide association studies in pharmacogenomics. <span><span class="ref-journal">Nat Rev Genet. </span>2010;<span class="ref-vol">11</span>:241–6.</span> [<a href="/pubmed/20300088" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20300088</span></a>]<div><i>(Review of recent advances in GWAS studies of pharmacokinetics and adverse drug reactions and association of flucloxacillin injury with HLA-B*5701).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.robles.2010.212">Robles M, Toscano E, Cotta J, Lucena MI, Andrade RJ. Antibiotic-induced liver toxicity: mechanisms, clinical features and causality assessment. <span><span class="ref-journal">Curr Drug Saf. </span>2010;<span class="ref-vol">5</span>:212–22.</span> [<a href="/pubmed/20210729" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20210729</span></a>]<div><i>(Review of antibiotic hepatotoxicity mentions that flucloxacillin is the second most common cause of liver injury in many countries).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.alam.2012.953714">Alam MB, Kadoura A, Sathaiah M. A fatal case of nafcillin-induced hepatotoxicity: a case report and the literature review. <span><span class="ref-journal">Case Rep Med. </span>2012;<span class="ref-vol">2012</span>:953714. </span> [<a href="/pmc/articles/PMC3403404/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3403404</span></a>] [<a href="/pubmed/22844299" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22844299</span></a>]<div><i>(53 year old woman developed jaundice 15 days after starting intravenous nafcillin for osteomyelitis [bilirubin 9.6 mg/dL, ALT 24 U/L, Alk P 388 U/L], with worsening despite stopping nafcillin [bilirubin 28.7 mg/dL, ALT 24 U/L, Alk P &#x0003e;1884 U/L], and death from multiorgan failure 2 months later).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.urban.2012.735">Urban TJ, Goldstein DB, Watkins PB. Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here? <span><span class="ref-journal">Pharmacogenomics. </span>2012;<span class="ref-vol">13</span>:735–8.</span> [<a href="/pmc/articles/PMC3641893/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3641893</span></a>] [<a href="/pubmed/22594502" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22594502</span></a>]<div><i>(Editorial summarizing recent advances in studies on the genetics of drug induced liver injury including the association of flucloxacillin injury with HLA-B*57:01).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.monshi.2013.727">Monshi MM, Faulkner L, Gibson A, Jenkins RE, Farrell J, Earnshaw CJ, Alfirevic A, et al.  Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. <span><span class="ref-journal">Hepatology. </span>2013;<span class="ref-vol">57</span>:727–39.</span> [<a href="/pubmed/22987284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22987284</span></a>]<div><i>(T cells from persons with HLA-B*57:01 were activated when exposed to dendritic cells presenting flucloxacillin bound to albumin, and were similarly activated by oxacillin, cloxacillin and dicloxacillin).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.sistanizad.2013.115">Sistanizad M, Peterson GM. Drug-induced liver injury in the Australian setting. <span><span class="ref-journal">J Clin Pharm Ther. </span>2013;<span class="ref-vol">38</span>:115–20.</span> [<a href="/pubmed/23350857" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23350857</span></a>]<div><i>(Among 17 persons with suspected drug induced liver injury seen over at 12 month period at a referral hospital in Tasmania, 11 were attributed to antibiotics including 4 to flucloxacillin, 2 amoxicillin with clavulanate, 2 amoxicillin, and 1 each to rifampin, moxifloxacin and ciprofloxacin).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.wuillemin.2013.4956">Wuillemin N, Adam J, Fontana S, Kr&#x000e4;henb&#x000fc;hl S, Pichler WJ, Yerly D. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin. <span><span class="ref-journal">J Immunol. </span>2013;<span class="ref-vol">190</span>:4956–64.</span> [<a href="/pubmed/23596311" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23596311</span></a>]<div><i>(Analysis of T cell responses in persons with and without HLA-B*57:01 suggested a pharmacological interaction of flucloxacillin with immune receptors on T cells, underlies the HLA association with flucloxacillin hepatoxicity).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.vera.2013.484">Vera JH, Naous N, Mackie N, Winston A, Cooke G. The safety of flucloxacillin in HIV-infected patients with positive HLA-B*5701 genotype. <span><span class="ref-journal">AIDS. </span>2013;<span class="ref-vol">27</span>:484–5.</span> [<a href="/pubmed/23032409" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23032409</span></a>]<div><i>(Among 10 persons with HIV infection with HLA-B*57:01 who received a course of flucloxacillin, none developed evidence of liver injury, suggesting that it is safe to use in this population of HLA-tested individuals).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.phillips.2013.491">Phillips EJ, Mallal SA. HLA-B*5701 and flucloxacillin associated drug-induced liver disease. <span><span class="ref-journal">AIDS. </span>2013;<span class="ref-vol">27</span>:491–2.</span> [<a href="/pubmed/23291545" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23291545</span></a>]<div><i>(Letter in response to Vera [2013] arguing that the positive predictive value of HLA-B*5701 is only 0.12%, making screening an inefficient means of avoiding flucloxacillin hepatotoxicity and accounting for their negative findings because of the few patients tested).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.kaniwa.2013.317">Kaniwa N, Saito Y. Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury. <span><span class="ref-journal">J Hum Genet. </span>2013;<span class="ref-vol">58</span>:317–26.</span> [<a href="/pubmed/23635947" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23635947</span></a>]<div><i>(Review of genetic studies of severe cutaneous and hepatic adverse events; HLA DRB*5701 has been associated with flucloxacillin hepatotoxicity, mainly in Europeans [Daly 2009]).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.bj_rnsson.2013.1419">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. <span><span class="ref-journal">Gastroenterology. </span>2013;<span class="ref-vol">144</span>:1419–25.</span> [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, including 36 [37%] due to antibiotics and specifically dicloxacillin in 1 of 22,320 patients treated and cloxacillin in 1 of 3659 patients treated).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.wuillemin.2014.1677">Wuillemin N, Terracciano L, Beltraminelli H, Schlapbach C, Fontana S, Kr&#x000e4;henb&#x000fc;hl S, Pichler WJ, et al.  T cells infiltrate the liver and kill hepatocytes in HLA-B(*)57:01-associated floxacillin-induced liver injury. <span><span class="ref-journal">Am J Pathol. </span>2014;<span class="ref-vol">184</span>:1677–82.</span> [<a href="/pubmed/24731753" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24731753</span></a>]<div><i>(Analysis of T cells from HLA-B*57:01 positive, healthy, non-flucloxacillin exposed controls demonstrated cytotoxicity of their CD8 cells by exposure to increasing concentrations of flucloxacillin with HLA-linked target cells).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.hern_ndez.2014.231">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al.  Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Systematic review of literature of drug induced liver injury from Latin American countries published between 1996 and 2012 identified 176 cases, of which 37 [19%] were attributed to antimicrobials, but none to penicillinase resistant penicillins such as oxacillin or dicloxacillin).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 323 cases [36%] were attributed to antibiotics 3 of which were due to oxacillin, all being self-limited episodes of aminotransferase elevations without jaundice; no instances of dicloxacillin or nafcillin associated liver injury).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.yaseen.2015.474">Yaseen FS, Saide K, Kim SH, Monshi M, Tailor A, Wood S, Meng X, et al.  Promiscuous T-cell responses to drugs and drug-haptens. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2015;<span class="ref-vol">136</span>:474–6.e8.</span> [<a href="/pubmed/25910715" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25910715</span></a>]<div><i>(T cell clones from patients with flucloxacillin induced liver injury are HLA-restricted and are activated by via a hapten mechanism, unlike T cells clones from HLA-allele matched healthy controls which are activated by the native drug).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.ram_rez.2015.360">Ram&#x000ed;rez A, Abril JC, Cano J. DRESS syndrome due to antibiotic therapy of osteoarticular infections in children: two case reports. <span><span class="ref-journal">Rev Esp Cir Ortop Traumatol. </span>2015;<span class="ref-vol">59</span>:360–4.</span> [<a href="/pubmed/25052739" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25052739</span></a>]<div><i>(2 children, aged 7 with septic arthritis and age 8 with osteomyelitis, developed fever and rash 7 and 16 days after starting cefotaxime and cloxacillin [ALT 55 and 281 U/L, bilirubin and Alk P not provided], resolving within 3 weeks of stopping antibiotics).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.faulkner.2016.416">Faulkner L, Gibson A, Sullivan A, Tailor A, Usui T, Alfirevic A, Pirmohamed M, et al.  Detection of primary T cell responses to drugs and chemicals in HLA-typed volunteers: implications for the prediction of drug immunogenicity. <span><span class="ref-journal">Toxicol Sci. </span>2016;<span class="ref-vol">154</span>:416–29.</span> [<a href="/pubmed/27637899" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27637899</span></a>]<div><i>(Demonstration of T cell priming to drugs linked with specific class I HLA-alleles).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.nicoletti.2017.1078">Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, et al. International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium.  Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. <span><span class="ref-journal">Gastroenterology. </span>2017;<span class="ref-vol">152</span>:1078–89.</span> [<a href="/pmc/articles/PMC5367948/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5367948</span></a>] [<a href="/pubmed/28043905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28043905</span></a>]<div><i>(A genome wide association study done on 862 patients with drug induced liver injury demonstrated a strong link with HLA-A*33:01 in patients with cholestatic liver injury, particularly in cases attributed to terbinafine, fenofibrate and ticlopidine).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.usui.2017.21">Usui T, Naisbitt DJ. Human leukocyte antigen and idiosyncratic adverse drug reactions. <span><span class="ref-journal">Drug Metab Pharmacokinet. </span>2017;<span class="ref-vol">32</span>:21–30.</span> [<a href="/pubmed/28017537" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28017537</span></a>]<div><i>(Review of the association of specific forms of idiosyncratic drug reactions and HLA alleles focusing on class I alleles linked with abacavir [B*57:01], allopurinol [B*58:01], carbamazepine [B*15:02], amoxicillin/clavulanate [A*02:01], and flucloxacillin [B*57:01]).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.rao.2017.564">Rao Q, Schuster I, Seoud T, Zarrabi K, Goolsarran N. A patient with nafcillin-associated drug-induced liver failure. <span><span class="ref-journal">Case Rep Gastroenterol. </span>2017;<span class="ref-vol">11</span>:564–8.</span> [<a href="/pmc/articles/PMC5636993/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5636993</span></a>] [<a href="/pubmed/29033779" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29033779</span></a>]<div><i>(68 year old man with osteomyelitis developed jaundice 4 weeks after starting intravenous nafcillin, 2 g every 4 hours [bilirubin 9.4 rising to 14.1 mg/dL, ALT 127 U/L, Alk P 311 U/L, INR 1.6, eosinophils 21%], worsening for 7 days after stopping, but then resolving and 6 months later had normal liver tests).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.wing.2017.2636">Wing K, Bhaskaran K, Pealing L, Root A, Smeeth L, van Staa TP, Klungel OH, et al.  Quantification of the risk of liver injury associated with flucloxacillin: a UK population-based cohort study. <span><span class="ref-journal">J Antimicrob Chemother. </span>2017;<span class="ref-vol">72</span>:2636–46.</span> [<a href="/pmc/articles/PMC5890755/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5890755</span></a>] [<a href="/pubmed/28859440" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28859440</span></a>]<div><i>(Among 861,962 individuals given a first prescription of flucloxacillin and followed for the next 45 days in the UK Clinical Practice Research Datalink, 122 developed symptoms of jaundice [14.2 per 100,000 or ~1 in 7000] and 73 had laboratory confirmed liver injury [8.5 per 100,000 or ~1 in 12,000], and rates were higher with consecutive prescriptions and in older age groups).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.visentin.2018.1498">Visentin M, Lenggenhager D, Gai Z, Kullak-Ublick GA. Drug-induced bile duct injury. <span><span class="ref-journal">Biochim Biophys Acta Mol Basis Dis. </span>2018;<span class="ref-vol">1864</span> 4 Pt B:1498–506.</span> [<a href="/pubmed/28882625" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28882625</span></a>]<div><i>(Review of drug induced bile duct injury focusing on agents flucloxacillin and amoxicillin/clavulanate that injure small ducts and fluorouracil [given by hepatic artery], ketamine, scolicidal agents [for Hydatid disease given into the cysts] that injure larger ducts causing a sclerosing cholangitis like picture).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.lavergne.2018.344">Lavergne A, Vigneau C, Polard E, Triquet L, Rioux-Leclercq N, Tattevin P, Golbin L. Acute kidney injury during treatment with high-dose cloxacillin: a report of 23 cases and literature review. <span><span class="ref-journal">Int J Antimicrob Agents. </span>2018;<span class="ref-vol">52</span>:344–9.</span> [<a href="/pubmed/29665445" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29665445</span></a>]<div><i>(Among 23 patients with suspected cloxacillin induced renal dysfunction [19 had also received gentamicin], the median age was 75, duration of therapy 4 days, dose 12 gm daily and peak creatinine 3.8 mg/dL, all resolving after stopping therapy; 8 patients had abnormal liver tests but no details provided).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.takeuchi.2018.1071">Takeuchi Y, Shinozaki T, Kumamaru H, Hiramatsu T, Matsuyama Y. Analyzing intent-to-treat and per-protocol effects on safety outcomes using a medical information database: an application to the risk assessment of antibiotic-induced liver injury. <span><span class="ref-journal">Expert Opin Drug Saf. </span>2018;<span class="ref-vol">17</span>:1071–9.</span> [<a href="/pubmed/30252549" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30252549</span></a>]<div><i>(Cohort matching of cases with vs without antibiotic therapy in a large electronic medical record database from the University of Tokyo Hospital from 2011 to 2015 with adjustments, found rates of liver test abnormalities within 30 days of starting penicillins [25.2 per 1000] were higher than that of fluoroquinolones [11.4] and macrolide antibiotics [8.1] as well as controls [6.5 to 7.1]).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.cirulli.2019.1707">Cirulli ET, Nicoletti P, Abramson K, Andrade RJ, Bjornsson ES, Chalasani N, Fontana RJ, et al. Drug-Induced Liver Injury Network (DILIN) investigators.  International DILI consortium (iDILIC). A missense variant in PTPN22 is a risk factor for drug-induced liver injury. <span><span class="ref-journal">Gastroenterology. </span>2019;<span class="ref-vol">156</span>:1707–1716.e2.</span> [<a href="/pmc/articles/PMC6511989/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6511989</span></a>] [<a href="/pubmed/30664875" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30664875</span></a>]<div><i>(Genome-wide association studies on 2048 patients with drug induced liver injury and 12,439 controls identified a variant in PTPN22 which was highly associated with liver injury, allele frequency being 0.12 among cases and 0.08 among controls with highest association in Northern Europeans and in cases of amoxicillin clavulanate, PTPN22 being a cellular kinase involved in modulation of immune reactions).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.nicoletti.2019.245">Nicoletti P, Aithal GP, Chamberlain TC, Coulthard S, Alshabeeb M, Grove JI, Andrade RJ, et al. International Drug-Induced Liver Injury Consortium.  (iDILIC). Drug-induced liver injury due to flucloxacillin: relevance of multiple human leukocyte antigen alleles. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2019;<span class="ref-vol">106</span>:245–53.</span> [<a href="/pubmed/30661239" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30661239</span></a>]<div><i>(Among 197 patients with flucloxacillin induced liver injury, the allele frequency for HLA-B*57:01 was 0.42 compared to 0.04 among population controls and HLA-B*57:03, although rare was also significantly associated with allele frequency of 0.005 compared to 0.0003 in controls, both B*57 alleles sharing a valine at position 97 of the HLA protein).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.hashim.2020.e233052">Hashim A, Barnabas A, Miquel R, Agarwal K. Successful liver transplantation for drug-induced vanishing bile duct syndrome. <span><span class="ref-journal">BMJ Case Rep. </span>2020;<span class="ref-vol">13</span>:e233052. </span> [<a href="/pmc/articles/PMC7035849/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7035849</span></a>] [<a href="/pubmed/31948982" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31948982</span></a>]<div><i>(63 year old man developed jaundice shortly after completing a 10 day course of flucloxacillin which worsened over the next 3 months [bilirubin 29.3 mg/dL, ALT 60 U/L, Alk P 229 U/L, INR 1.0], liver biopsy showing bland cholestasis and rare bile duct loss, eventually undergoing successful liver transplant 6 months after presentation; genetic testing revealed homozygosity for a BSEP [ABC B11] mutation which may have contributed to the poor outcome).</i></div></div></li><li><div class="bk_ref" id="PenicillinSecondGen.REF.teixeira.2020.12">Teixeira M, Macedo S, Batista T, Martins S, Correia A, Matos LC. Flucloxacillin-induced hepatotoxicity - association with HLA-B*5701. <span><span class="ref-journal">Rev Assoc Med Bras. </span>2020;<span class="ref-vol">66</span>(1):12–7.</span> [<a href="/pubmed/32130375" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32130375</span></a>]<div><i>(74 year old man developed abdominal pain 2 weeks after a second 8 day course of flucloxacillin [bilirubin 3.3 rising to 24.1 mg/dL, ALT 646 U/L, Alk P 302 U/L, GGT 662 U/L] with persistence of jaundice for 3 months and abnormalities of Alk P and GGT for more than a year; HLA testing revealed B*57:01, an allele often associated with flucloxacillin liver injury).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548033</span><span class="label">PMID: <a href="/pubmed/31643364" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643364</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/PenicillinFirstGen/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/PenicillinThirdGen/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548033&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548033/?report=reader">PubReader</a></li><li><a href="/books/NBK548033/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548033" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548033" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Penicillins (2nd Generation) [Updated 2020 Oct 20].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548033/pdf/Bookshelf_NBK548033.pdf">PDF version of this page</a> (194K)</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=(dicloxacillin/AE+OR+nafcillin/AE+OR+oxacillin/AE+OR+cloxacillin/AE+OR+flucloxacillin/AE+OR+methicillin/AE)+AND+Human%5BMH%5D+AND+(jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI+OR+hepatitis,+toxic%5BMH%5D)+AND+(%222008/03/01%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Penicillinase-Resistant Penicillins: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=dicloxacillin+OR+nafcillin+OR+oxacillin+OR+cloxacillin+OR+flucloxacillin+OR+methicillin" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Penicillinase-Resistant Penicillins: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4861072" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4861072" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4861072" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/5481218" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Flucloxacillin, a new isoxazolyl penicillin, compared with oxacillin, cloxacillin, and dicloxacillin.</a><span class="source">[Br Med J. 1970]</span><div class="brieflinkpop offscreen_noflow">Flucloxacillin, a new isoxazolyl penicillin, compared with oxacillin, cloxacillin, and dicloxacillin.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sutherland R, Croydon EA, Rolinson GN. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Br Med J. 1970 Nov 21; 4(5733):455-60. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/3489704" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Relationship between penicillinase production and the in-vitro activity of methicillin, oxacillin, cloxacillin, dicloxacillin, flucloxacillin, and cephalothin against strains of Staphylococcus aureus of different phage patterns and penicillinase activity.</a><span class="source">[J Antimicrob Chemother. 1986]</span><div class="brieflinkpop offscreen_noflow">Relationship between penicillinase production and the in-vitro activity of methicillin, oxacillin, cloxacillin, dicloxacillin, flucloxacillin, and cephalothin against strains of Staphylococcus aureus of different phage patterns and penicillinase activity.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Frimodt-Møller N, Rosdahl VT, Sørensen G, Hartzen SH, Bentzon MW. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Antimicrob Chemother. 1986 Jul; 18(1):27-33. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/7041278" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Comparison of oral penicillinase-resistant penicillins: contrasts between agents and assays.</a><span class="source">[South Med J. 1982]</span><div class="brieflinkpop offscreen_noflow">Comparison of oral penicillinase-resistant penicillins: contrasts between agents and assays.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bass JW, Bruhn FW, Merritt WT, Suttle DE, Jirka JH, Mesrobian RB, Berkenbaugh JT. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">South Med J. 1982 Apr; 75(4):408-10. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/318800" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics. Part 2: penicillins.</a><span class="source">[Am J Hosp Pharm. 1977]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Antimicrobial spectrum, pharmacology and therapeutic use of antibiotics. Part 2: penicillins.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Barza M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Am J Hosp Pharm. 1977 Jan; 34(1):57-67. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643749" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Penicillins (4th Generation)</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Penicillins (4th Generation)<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643364" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643364" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60468e2d4664552c12ce1d7c">Penicillins (2nd Generation) - LiverTox</a><div class="ralinkpop offscreen_noflow">Penicillins (2nd Generation) - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T15:50:53-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal106&amp;ncbi_phid=CE8DDE0504671B2100000000065F01D8&amp;ncbi_session=CE8DDE050468E2D1_1631SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548033%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548033&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548033/&amp;ncbi_pagename=Penicillins (2nd Generation) - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8DDE050468E2D1_1631SID /projects/books/PBooks@9.2 portal106 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>